Skip to main content
Loading

Drusolv Therapeutics, Inc.

October 18, 2023
Franciscan D
Ophthalmology
Drusolv Therapeutics is a clinical-stage drug company based in Philadelphia. We are repurposing oral atorvastatin (using a novel formulation) for the new indication of early intervention in age-related macular degeneration (AMD). Our target is patients who are still in the intermediate stages of the disease and currently have very limited options to prevent progression to late-stage blindness. This is a $13bn per year, completely unmet need.
Speakers
John Edwards - Drusolv Therapeutics, Inc.

Company Type

Privately Funded

Website

https://www.linkedin.com/company/drusolv-therapeutics/

CEO/Top Company Official

John Edwards

Lead Product in Development

Ocustatin (novel reformulation of atorvastatin for early intervention in AMD)

Number Of Unlicensed Products

One

BIO DOUBLE HELIX SPONSOR

BIO HELIX SPONSOR

CONFERENCE SPONSORS